InvestorsHub Logo
Followers 8
Posts 1891
Boards Moderated 0
Alias Born 05/05/2016

Re: FDApproved post# 18288

Monday, 11/12/2018 10:55:13 AM

Monday, November 12, 2018 10:55:13 AM

Post# of 44784

Elevated Levels Of C-Reactive Protein



With PLX-PAD --> down 48%
Placebo --> up 95%

Note: C-Reactive Protein (CRP) is a major signal for ALL inflammatory syndromes (from heart disease to IBD!!!).

For me the impressive part is once more the versatility of MSCs in responding to a wide variety of dysregulated physiological functions. This medicine is ALIVE!! and it responds as needed, based on standard distress signaling mechanisms. The dramatic impact of PLX-PAD on CRP levels is a very encouraging indicator that Pluristem's medicine is providing valuable benefit for very sick patients. Again, we get corroboration from the best researchers in the field.

Our in house experts (LOL!!!!!!!) "AutoEich999" cannot BELIEB their own eyes. They're VERY skeptical indeed! They're "LMBO" and call executives "Kaki" and keep saying "DEAD MONEY" and "PATHETIC" to counter clinical evidence, produced by actual experts! PATHETIC!!!

Simple DD:

C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood. CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation.

This so-called acute phase response occurs as a result of a rise in the concentration of IL-6, which is produced by macrophages[6] as well as adipocytes[7] in response to a wide range of acute and chronic inflammatory conditions such as bacterial, viral, or fungal infections; rheumatic and other inflammatory diseases; malignancy; and tissue injury and necrosis.